Survival of Patients With Gastroenteropancreatic Neuroendocrine Tumors and Diabetes Mellitus.

Objectives: Diabetes mellitus (DM) is associated with an increased risk of gastroenteropancreatic neuroendocrine tumors (GEP-NETs), but the association between DM and GEP-NET survival is unknown. We evaluated disease characteristics and survival in individuals with DM and GEP-NETs.
Methods: Using the Surveillance, Epidemiology, and End Results registry linked to Medicare (SEER-Medicare) claims database, we examined sociodemographics, GEP-NET characteristics, and treatment in patients with and without DM before GEP-NET diagnosis. We compared survival using univariate and multivariate analyses.
Results: We identified 1858 individuals with GEP-NETs: 478 (25.7%) with DM and 1380 (74.3%) without. Significant differences in race (P = 0.002) were found between the DM and non-DM groups. Compared with individuals without DM, those with DM had more gastric (9.7% vs 14.9%), duodenal (6.5% vs 10.0%), and pancreatic (17.0% vs 21.8%), and less jejunal/ileal (18.1% vs 12.8%) NETs (P < 0.0001). Patients with DM had earlier stages (stage I, 37.0%; stage IV, 30.8%) than those without (stage I, 30.6%; stage IV, 36.4%; P = 0.0012). We found no difference in survival (multivariate hazard ratio, 0.97; 95% confidence interval, 0.76-1.23) between groups.
Conclusions: Among patients with and without DM before GEP-NET diagnosis, we found differences in tumor location and stage, but not survival.
Competing Interests: E.J.G. has served on an advisory board for Novartis and as a consultant for Seattle Genetics and SynDevRx for work unrelated to this project. S.T., K.B., and M.K.K. have no conflicts of interest that could be perceived as prejudicing the impartiality of the research reported.
(Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.)